Quantification of pre-treatment positive elements in BM biopsies correlated with risk of progression to AML, with higher percentages of p53-positive elements before treatment (mean 4.7%) among progressed patients (p = 0.001) compared to the ones without progression (mean 0.8%). The gene discussed is TP53; the disease is acute myeloid leukemia.